OS Animal Health delivered a key corporate presentation today at the Disruptive Growth & Life Sciences Conference, outlining its pipeline focused on novel therapeutics for agricultural livestock and companion animal health.
The presentation highlighted the company’s advancing platform of small-molecule therapeutics designed to enhance gut integrity, improve metabolic performance, and serve as non-antibiotic antimicrobial alternatives in swine and poultry production.
Strategic Shift Toward Alternative Antimicrobials
With regulatory pressures tightening global access to traditional sub-therapeutic antibiotics in food-animal production, OS Animal Health’s platform addresses the demand for sustainable monogastric production therapies.
Key Presentation Highlights
-
Gut Integrity Protection: The small-molecule platform focuses on reinforcing the intestinal epithelial barrier in swine and poultry, mitigating damage caused by necrotic enteritis, heat stress, and diet transitions.
-
Targeted Non-Antibiotic Action: Therapeutics are designed to selectively suppress pathogenic bacterial proliferation while preserving beneficial gut microbiota, offering a scalable alternative to traditional medically important antibiotics.
-
Biosecurity & Operational Efficiency: By optimizing feed efficiency and reducing disease-related mortality in young livestock, the pipeline aims to lower overall cost-of-gain for commercial producers.
